Live-attenuated respiratory syncytial virus vaccines

Ruth A Karron, Ursula J. Buchholz, Peter L. Collins

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.

Original languageEnglish (US)
Title of host publicationCurrent Topics in Microbiology and Immunology
Pages259-284
Number of pages26
Volume372
DOIs
StatePublished - 2013

Publication series

NameCurrent Topics in Microbiology and Immunology
Volume372
ISSN (Print)0070217X

Fingerprint

Respiratory Syncytial Virus Vaccines
Attenuated Vaccines
Respiratory Syncytial Viruses
Parainfluenza Vaccines
Respiratory System
Vaccines
Serial Passage
Reverse Genetics
Membrane Glycoproteins
Virus Diseases
Humoral Immunity
Neutralizing Antibodies
Innate Immunity
Cellular Immunity
Mutagenesis
Immunization

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology

Cite this

Karron, R. A., Buchholz, U. J., & Collins, P. L. (2013). Live-attenuated respiratory syncytial virus vaccines. In Current Topics in Microbiology and Immunology (Vol. 372, pp. 259-284). (Current Topics in Microbiology and Immunology; Vol. 372). https://doi.org/10.1007/978-3-642-38919-1-13

Live-attenuated respiratory syncytial virus vaccines. / Karron, Ruth A; Buchholz, Ursula J.; Collins, Peter L.

Current Topics in Microbiology and Immunology. Vol. 372 2013. p. 259-284 (Current Topics in Microbiology and Immunology; Vol. 372).

Research output: Chapter in Book/Report/Conference proceedingChapter

Karron, RA, Buchholz, UJ & Collins, PL 2013, Live-attenuated respiratory syncytial virus vaccines. in Current Topics in Microbiology and Immunology. vol. 372, Current Topics in Microbiology and Immunology, vol. 372, pp. 259-284. https://doi.org/10.1007/978-3-642-38919-1-13
Karron RA, Buchholz UJ, Collins PL. Live-attenuated respiratory syncytial virus vaccines. In Current Topics in Microbiology and Immunology. Vol. 372. 2013. p. 259-284. (Current Topics in Microbiology and Immunology). https://doi.org/10.1007/978-3-642-38919-1-13
Karron, Ruth A ; Buchholz, Ursula J. ; Collins, Peter L. / Live-attenuated respiratory syncytial virus vaccines. Current Topics in Microbiology and Immunology. Vol. 372 2013. pp. 259-284 (Current Topics in Microbiology and Immunology).
@inbook{e7c0103afc0b4d389115ece29df135d8,
title = "Live-attenuated respiratory syncytial virus vaccines",
abstract = "Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.",
author = "Karron, {Ruth A} and Buchholz, {Ursula J.} and Collins, {Peter L.}",
year = "2013",
doi = "10.1007/978-3-642-38919-1-13",
language = "English (US)",
isbn = "9783642389184",
volume = "372",
series = "Current Topics in Microbiology and Immunology",
pages = "259--284",
booktitle = "Current Topics in Microbiology and Immunology",

}

TY - CHAP

T1 - Live-attenuated respiratory syncytial virus vaccines

AU - Karron, Ruth A

AU - Buchholz, Ursula J.

AU - Collins, Peter L.

PY - 2013

Y1 - 2013

N2 - Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.

AB - Live-attenuated respiratory syncytial virus (RSV) vaccines offer several advantages for immunization of infants and young children: (1) they do not cause vaccine-associated enhanced RSV disease; (2) they broadly stimulate innate, humoral, and cellular immunity, both systemically and locally in the respiratory tract; (3) they are delivered intranasally; and (4) they replicate in the upper respiratory tract of young infants despite the presence of passively acquired maternally derived RSV neutralizing antibody. This chapter describes early efforts to develop vaccines through the classic methods of serial cold-passage and chemical mutagenesis, and recent efforts using reverse genetics to derive attenuated derivatives of wild-type (WT) RSV and to develop parainfluenza vaccine vectors that express RSV surface glycoproteins.

UR - http://www.scopus.com/inward/record.url?scp=84892767243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892767243&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-38919-1-13

DO - 10.1007/978-3-642-38919-1-13

M3 - Chapter

C2 - 24362694

AN - SCOPUS:84892767243

SN - 9783642389184

VL - 372

T3 - Current Topics in Microbiology and Immunology

SP - 259

EP - 284

BT - Current Topics in Microbiology and Immunology

ER -